RLT Patient Referral Pathways for Prostate Cancer (Mar. 2026)

Consensus Project on Optimising RLT Patient Referral Pathways for Prostate Cancer

EANM is pleased to highlight the launch of the Consensus Project on Optimising RLT Patient Referral Pathways for Prostate Cancer.

The initiative brings together six leading European medical societies—EANM, the European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Radiology (ESR)—alongside patient advocates from Europa Uomo. This unprecedented multidisciplinary collaboration, led by EANM, aims to define harmonised, efficient, and equitable referral pathways for Radioligand Therapy (RLT), an emerging precision oncology approach that combines molecular diagnostics with targeted treatment.

While RLT is now an established option for advanced prostate cancer, clinical pathways across Europe have yet to fully adapt. This gap impacts equitable access, resource allocation, and patient outcomes. In response to the EU Cancer Mission’s call for implementation-oriented action, the project focuses not on clinical efficacy, but on improving system-level coordination and referral processes.

Through a structured, multi-step consensus process—including a Steering Group, Writing Group, Delphi Panel, and Reading Group—the initiative will develop a joint European position on when, how, and by whom patients should be referred for RLT across the care continuum. The final consensus statement will be published simultaneously in open access across all partner journals, marking a significant milestone in cross-specialty European collaboration.

The project plans to conclude with a comprehensive dissemination strategy, potentially including presentations at major congresses, endorsements by additional stakeholders, and integration into clinical decision-support tools to support practical implementation across Europe.

EANM sincerely thanks the leadership of all participating scientific societies and patient advocacy groups for their commitment and invaluable contributions to this collaborative effort. Their dedication is key to advancing more integrated, equitable, and patient-centered prostate cancer care across Europe.

For further information, please contact EANM Strategy Implementation Director Silvia Marchetti at s.marchetti@eanm.org.

Published online: March 24, 2026.